Cancer drug combination overcomes treatment resistance in new study
Fox News••health
Key Points:
- Researchers at Oregon Health and Science University discovered that combining venetoclax, a leukemia drug, with palbociclib, a breast cancer drug, significantly enhances treatment effectiveness against acute myeloid leukemia (AML) compared to venetoclax alone.
- The drug combination was tested on over 300 patient samples and mouse models, showing improved leukemia-fighting activity and overcoming resistance seen in current frontline therapies.
- The study revealed that palbociclib blocks AML cells' adaptive increase in protein production, which typically leads to resistance against venetoclax treatment.
- Despite promising preclinical results, clinical trials are needed to confirm the combination's effectiveness in AML patients, as current five-year survival rates remain low at
